Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Procrit Will Rely On New Indications, DTC To Compete With Amgen NESP

Executive Summary

Johnson & Johnson is focusing on consumer education and line extensions to position Procrit for impending competition from Amgen's NESP.
Advertisement

Related Content

J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram
J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram
Amgen Working With Payors To Identify NESP Patients At Primary Care Level
Amgen Working With Payors To Identify NESP Patients At Primary Care Level
Pain Therapeutics To Enter Opioid Painkiller Market In 2003
Pain Therapeutics To Enter Opioid Painkiller Market In 2003
J&J Product Targeting Histamine H3 Receptor Moves Into Clinic
J&J Product Targeting Histamine H3 Receptor Moves Into Clinic
Advertisement
UsernamePublicRestriction

Register

PS036378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel